Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
1.880
+0.110 (6.21%)
At close: Jun 26, 2026, 4:00 PM EDT
1.887
+0.007 (0.37%)
After-hours: Jun 26, 2026, 7:50 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 16 employees as of December 31, 2025. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$2,352,563
Market Cap
16.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 15 | 0 |
| Dec 31, 2023 | 12 | 1 | 9.09% | 12 | 0 |
| Dec 31, 2022 | 11 | 3 | 37.50% | 11 | 0 |
| Dec 31, 2021 | 8 | 0 | - | 6 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| Moleculin Biotech | 17 |
| Werewolf Therapeutics | 14 |
| BioVie | 13 |
| Tempest Therapeutics | 5 |
| Exicure | 2 |
ATOS News
- 15 days ago - Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PRNewsWire
- 16 days ago - Atossa Therapeutics announces registered direct offering of up to $16.5M - TheFly
- 16 days ago - Atossa Therapeutics announces $16.5M registered direct offering - TheFly
- 16 days ago - Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PRNewsWire
- 4 weeks ago - Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PRNewsWire
- 5 weeks ago - Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - PRNewsWire
- 5 weeks ago - Atossa Therapeutics Transcript: Status update - Transcripts
- 6 weeks ago - Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer - PRNewsWire